$CFBK

CF Bankshares Inc. (NASDAQ:CFBK) Short Interest Down 18.9% in April

CF Bankshares Inc. (NASDAQ:CFBK) experienced an 18.9% decline in short interest in April, totaling 53,497 shares, which represents 1.1% of its shares short and a 2.1-day short-interest ratio. Institutional ownership stands at 41.06%, with significant increases from HSBC and Quadrature and a new position from Man Group. Analysts generally maintain a "Moderate Buy" rating with a $34 consensus price target, following a Weiss Ratings upgrade and Piper Sandler raising its price target.

Original reporting
MarketBeat · MarketBeat
Published May 1, 2026, 8:10 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 1, 2026, 8:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
CF Bankshares Inc. (NASDAQ:CFBK) Short Interest Down 18.9% in April — source image
Decision brief

The 30-second read

$CFBKBullishMed
01

Why it matters

The decrease in short interest is likely to support a price rally, especially with positive analyst upgrades and increased institutional holdings.

02

Market read

The news indicates a positive shift in sentiment for CF Bankshares, with potential short-term trading opportunities, though broader market impact remains limited.

03

What to watch

Potential for short-term profit-taking or external macroeconomic factors that could negate positive sentiment.

Relevance 6/10Timing: short-term (1-4 weeks)

Background

CF Bankshares Inc. has experienced fluctuating short interest levels; recent decline suggests shifting investor sentiment.

Company-level read

Ticker impact

$CFBKBullishHigh confidence
Context

The news highlights a significant decrease in short interest for CF Bankshares Inc., indicating potential positive market sentiment and reduced bearish pressure.

Expected impact

Moderate upward movement expected over the next 2-4 weeks, approximately 3-5% increase in stock price.

Evidence & confidence

The substantial reduction in short interest coupled with analyst upgrades and increased institutional ownership signals bullish sentiment, likely to support price appreciation.

Market effects

The financial sector may experience increased investor interest, potentially benefiting regional banking stocks.

Primarily affecting the U.S. regional banking sector; limited global impact.

Negligible; the news pertains mainly to a regional bank with no immediate global implications.

Counterpoint

The decline in short interest may be a temporary correction; underlying fundamentals could be weakening, warranting caution.

Key entities

  • CF Bankshares Inc.

    A regional bank listed on NASDAQ.

  • HSBC

    A major banking and financial services organization increasing its stake.

  • Quadrature

    An investment firm increasing its holdings in CF Bankshares.

  • Man Group

    A new institutional investor establishing a position in CF Bankshares.

Related articles

$CFBKMed

CF BANKSHARES INC., PARENT OF CFBANK NA, REPORTS RESULTS FOR THE 2nd QUARTER 2026

CF BANKSHARES INC. (CFBK) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 cfbk-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Parent of CFBank, NA PRESS RELEASE FOR IMMEDIATE RELEASE: July 28, 2026 For Further Information: Timothy T. O'Dell, President & CEO Phone: 614.318.4660 Email: timodell@cfbankmail.com CF BANKSHARES INC., PARENT OF CFBANK NA, R

$GLUEMedAI 8/10

Monte Rosa's MRT-8102 Drives 80%-90% NEK7 Degradation In Phase 1

Monte Rosa Therapeutics (GLUE) reported Phase 1 results showing MRT-8102 achieved 80%-90% NEK7 degradation, reducing biomarkers linked to cardiovascular disease. The treatment was well-tolerated with no serious adverse events. GLUE plans Phase 2 trials in 2026-2027 for coronary artery disease, gout, and hidradenitis suppurativa. GLUE stock is currently down 5.74% at $11.24.

$HDBMed

Top 10@10 | D-Street’s losing streak hits 8 weeks, HDFC Bank and Kotak get new CEOs, Tata Trusts flag concerns

HDFC Bank appointed Anup Bagchi as MD & CEO for a 3-year term, approved by RBI. Kotak Mahindra Bank received RBI approval for Anup Kumar Saha as next MD & CEO, effective January 1, 2027. Tata Trusts raised concerns over a proposed restructuring at Tata Sons. IRDAI aims to improve insurance sector efficiency, while Mahindra reported a 15% increase in September auto sales.